By selecting the 'Yes, leave Amgen.co.th option you understand that you are leaving the corporate page of Amgen Thailand and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Thailand is not responsible for and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Thailand. If you reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
With a presence in more than 100 countries, every year we reach millions of patients around the world.
At Amgen we take advantage of the full potential of biotechnology to collaborate and provide new tools for clinical practice. In Thailand, we focus on the following therapeutic areas:
In general medicine, Amgen is a leader in bone health with more than 20 years of osteoporosis research experience and is committed to combat this disease to help people at high risk of fracture, to reduce their risks at first or subsequent fracture.
Every three seconds, a bone breaks due to osteoporosis somewhere in the world.1
Osteoporosis is a common skeletal condition that causes low bone mass and deterioration of bone2 . Changes in the balance between degradation and build-up of bone tissue leads to the bone becoming increasingly fragile, raising the risk of fractures. Osteoporosis causes more than 8.9 million fractures annually worldwide3 mostly in post-menopausal women. As Thailand’s population ages, incidence of the disease is growing4.
An osteoporosis-related fracture can be life-altering5. After an initial bone break, approximately 80% of patients remain undiagnosed and untreated6. One way to help ensure that more people are diagnosed and treated for the disease following a fracture is to implement more outpatient post-fracture care coordination programs around the world7,8. These programs are designed to help people who have experienced an osteoporosis-related fracture receive the appropriate information and care to help prevent future fractures before they occur.
Amgen has worked with hospitals in Asia Pacific to establish Fracture Liaison Service (FLS) to improve the diagnosis and treatment of osteoporosis. In Thailand, the first FLS was launched in 2018 as a collaboration between Amgen, the Ministry of Public Health and Lerdsin Hospital, a centre of excellence for orthopaedics. The programme has since expanded to 121 hospitals in Thailand, with nearly 2,000 patients recruited and 500 healthcare professionals participating in professional development activities such as meetings, workshops, and online communities.
Cardiovascular diseases, which involve the heart and blood vessels, accounted for 23 per cent of all deaths in Thailand in 20169 .
Atherosclerosis is the buildup of fats, cholesterol and other substances in and on the artery walls that carry oxygenated blood from the heart to other parts of the body, is the most common cause of cardiovascular disease10. It is caused by genetics and lifestyle factors such as unhealthy diet, smoking or heavy consumption of alcoholic beverages. A large proportion of all cardiovascular diseases can be prevented by reducing salt intake, increasing consumption of fruits and vegetables, reducing alcohol intake, exercising regularly, and avoid smoking.
In addition, diabetes mellitus, High blood pressure and lipid lowering medications have been shown to contribute to reducing CV risks. This is especially true in hereditary cardiovascular disease where cardiovascular events occur independently from lifestyle habits. This includes, for example, hereditary blood lipid disorders such as familial hypercholesterolemia.
Amgen has a portfolio of innovative products and biosimilars for the treatment of oncological and hematological diseases, such as colorectal cancer, leukemia and multiple myeloma.
Amgen developed medicines in the field of inflammation, and we are currently discovering innovative molecules to treat chronic inflammatory diseases. Some of the conditions to which we provide solutions are for autoimmune pathologies such as rheumatoid arthritis and psoriasis, which affect millions of patients in the world. Inflammation is another field in which Amgen has biosimilars approved to improve healthcare costs in chronic diseases.
For information on the drugs that are in development, we invite you to visit our pipeline.